Business Context and Reporting Period
This Form 8-K concerns Anzu Special Acquisition Corp I, not Envoy Medical, Inc. The report covers events on March 1–4, 2021, related to Anzu’s initial public offering and formation activities. Anzu is a special purpose acquisition company seeking an initial business combination.
Key Financial and Capitalization Metrics
- IPO: 42,000,000 units sold at $10.00 per unit, generating gross proceeds of $420.0 million.
- Each unit consisted of one Class A common share and one-third of a warrant. Each whole warrant is exercisable at $11.50 per share, subject to adjustment.
- Underwriters received a 45-day option to purchase up to 6,300,000 additional units.
- Private placement: 12,400,000 warrants sold to the sponsor at $1.00 per warrant, generating gross proceeds of $12.4 million. Up to 1,260,000 additional private placement warrants may be sold if the over-allotment option is exercised.
- The filing states that $420.0 million, comprising the net IPO proceeds and private placement proceeds, was deposited into a U.S.-based trust account.
- Initial stockholders held 12,075,000 shares of Class B common stock after a 2,012,500-share stock dividend; up to 1,575,000 shares may be forfeited if the over-allotment option is not exercised.
- The filing does not provide revenue, operating profit, net income, cash flow, margins, or debt balances.
Material Changes and Unusual Items
- The IPO registration statement became effective on March 1, 2021, and a Rule 462(b) registration statement was filed the same day.
- The IPO closed on March 4, 2021. An amended and restated certificate of incorporation was filed on March 3, 2021.
- Proceeds were placed in a trust account and generally cannot be released until completion of an initial business combination, certain approved amendments involving redemption rights, or redemption of public shares if no business combination is completed within 24 months after the IPO closing.
- The company entered into underwriting, warrant, trust, registration rights, administrative services, sponsor warrant purchase, letter, and director and officer indemnification agreements.
- Private placement warrants have transfer restrictions, registration rights, cashless exercise rights, and specified redemption protections while held by the sponsor or permitted transferees.
Guidance, Outlook, and Risks
The filing provides no financial guidance or operating forecast. The principal stated objective is to complete an initial business combination within 24 months of the IPO closing. If that does not occur, public shares are generally subject to redemption, subject to applicable law and the governing charter provisions. The trust account restrictions, redemption provisions, potential forfeiture of founder shares, warrant dilution, and dependence on completing a suitable business combination are material considerations.
Investor Verification Items
- Verify the correct issuer: the provided filing is for Anzu Special Acquisition Corp I, while the request identifies Envoy Medical, Inc.
- Confirm the final number of IPO units and private placement warrants after any exercise of the over-allotment option.
- Reconcile the stated $420.0 million trust deposit with IPO expenses, net IPO proceeds, and private placement proceeds.
- Review the trust agreement and charter for redemption mechanics and the precise 24-month business-combination deadline.
- Assess the dilution and transfer terms associated with founder shares, public warrants, and private placement warrants.